Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

Part of paid clinical trials in Richmond, Virginia.

Sponsor
Virginia Commonwealth University
Study ID
NCT05263492
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lenvatinib — DRUG
    Lenvatinib once a day by mouth every day
  • Pembrolizumab — DRUG
    Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.

Study Details

Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants

Key Dates

Start date
Apr 1, 2022
Status verified
Sep 2025
Primary completion
Sep 13, 2024
Completion
Oct 19, 2024

Study Design

Enrollment
4 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab & Lenvatinib
    Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.

Primary Outcome Measure

Determine the Objective Response Rate (ORR) at 24 Weeks in Black Patients With Recurrent Endometrial Cancer Treated With Lenvatinib 20 mg Orally Daily in Combination With Pembrolizumab 200 mg IV Every 3 Weeks [ Time Frame: 24 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Virginia Commonwealth UniversityRichmondVirginia23298-

Related coverage on Hipa.ai

Find similar trials in Richmond, VA

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Virginia Commonwealth University· Richmond, VA

Related Studies